Cargando…
Transport characteristics of a novel peptide platform for CNS therapeutics
New and effective therapeutics that cross the blood-brain barrier (BBB) are critically needed for treatment of many brain diseases. We characterize here a novel drug development platform that is broadly applicable for the development of new therapeutics with increased brain penetration. The platform...
Autores principales: | Bertrand, Yanick, Currie, Jean-Christophe, Demeule, Michel, Régina, Anthony, Ché, Christian, Abulrob, Abedelnasser, Fatehi, Dorothy, Sartelet, Hervé, Gabathuler, Reinhard, Castaigne, Jean-Paul, Stanimirovic, Danica, Béliveau, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822732/ https://www.ncbi.nlm.nih.gov/pubmed/19818094 http://dx.doi.org/10.1111/j.1582-4934.2009.00930.x |
Ejemplares similares
-
Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
por: Bertrand, Y, et al.
Publicado: (2011) -
Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer's Disease
por: Leclerc, Benoît, et al.
Publicado: (2013) -
Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity
por: Caron, Nicholas S, et al.
Publicado: (2022) -
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
por: Demeule, Michel, et al.
Publicado: (2022) -
TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
por: Demeule, Michel, et al.
Publicado: (2021)